Natural helicid (4-formylphenyl-O-b-D-allopyranoside), a main active constituent from seeds of the Chinese herb Helicia nilagirica, has been reported to exert a sedative, analgesic and hypnotic effect, and is used clinically to treat neurasthenic syndrome, vascular headaches and trigeminal neuralgia. In the current study, mechanical allodynia tests, electroencephalograms, electromyogram recordings and c-Fos expression in neuropathic pain-like model mice of partial sciatic nerve ligation were used to investigate the effect of helicid on neuropathic pain and co-morbid insomnia. Our results showed that helicid at a dose of 100, 200 or 400 mg kg À1 could increase the mechanical threshold by 2.5-, 2.8-and 3.1-fold for 3 h after administration, respectively. Helicid at 200 and 400 mg kg À1 given at 07:00 hours increased the amount of non-rapid eye movement sleep in a 3-h period by 1.27-and 1.35-fold in partial sciatic nerve ligated mice. However, helicid (400 mg kg À1 ) given at 21:00 hours did not change the sleep pattern in normal mice. Immunohistochemical study showed that helicid (400 mg kg À1 ) administration could reverse the increase of c-Fos expression in the neurons of the rostral anterior cingulate cortex and tuberomammillary nucleus, and the decrease of c-Fos expression in the ventrolateral preoptic area caused by partial sciatic nerve ligation. These results indicate that helicid is an effective agent for both neuropathic pain and sleep disturbances in partial sciatic nerve ligated mice.
IN TROD UCTI ON
Neuropathic pain initiated by a primary lesion or dysfunction in the peripheral or central nervous system is characterized by spontaneous pain, hyperalgesia and allodynia. It is one of the most difficult types of chronic pain to treat (Niederberger et al., 2008) . Patients with neuropathic pain and other chronic pain experience prevalent and recurring sleep disturbances. Co-morbid insomnia with chronic pain has caused significant reductions in the quality of life (Smith et al., 2000) . Previous studies suggest an interrelationship between sleep disturbances and chronic pain (Argoff, 2007) . Alleviation of neuropathic pain could improve sleep interference for many people, and did not cause subsequent depression or somnolence (Fishbain et al., 2008) .
In clinics, first-line medications for the treatment of chronic pain with co-morbid insomnia are opioid analgesics or sedative pain drugs, including tricyclic antidepressants and anticonvulsants. Studies indicate that most of these can effectively alleviate pain, but do not ameliorate sleep disturbances (Argoff, 2007) . Benzodiazepine receptors, melatonin receptors and histamine receptor agonists are also used. However, side-effects, such as dizziness, nausea, daytime somnolence, risk of dependence, and memory, cognitive and psychomotor impairment, make them inappropriate for longterm use (Argoff, 2007; Neubauer, 2013) . Natural helicid, 4-formylphenyl-O-b-D-allopyranoside ( Fig. 1 ; Yi et al., 2008) , is one of the main active constituents from the seeds of Helicia nilagirica, an indigenous herb in western China (Liu et al., 2005) . Investigations reported that helicid has sedative, analgesic and hypnotic effects Yi et al., 2008) . Helicid is found to alleviate the increase of glutamine and the reduction of c-amino acid butyric acid (GABA)/glutamate caused by thiosemicarbazide in the whole brain and synapses, and to influence the activity of glutamic pyruvic transaminase and glutamine synthetase ª 2017 European Sleep Research Society (Zhou et al., 1987) . Another study reported that the aglycon of helicid, 4-hydroxybenzaldehyde, is a potent antioxidant agent and GABA transaminase inhibitor (Ha et al., 2001) . The low toxicity and few side effect make this agent unique. A neurotoxicological teratology study reported that intragastric administration of helicid with a dose as high as 305 mg kg À1 did not affect early nervous system development, neurobehavioural functions or brain histology of rats' offspring (Jia et al., 2010) . Now, it has been used clinically to treat neurasthenic syndromes, vascular headaches and trigeminal neuralgia in China (Jia et al., 2010 (Jia et al., , 2015 .
In the present study, the effects of helicid on neuropathic pain and co-morbid insomnia were evaluated in mice with partial sciatic nerve ligation (PSL), a model imitating neuropathic pain in humans . In addition, we observed the expression of c-Fos in the rostral (but not caudal) anterior cingulate cortex (rACC), which is implicated in encoding negative affective components of nociceptor stimulation (Johansen et al., 2001; Qu et al., 2011) , and the ventrolateral preoptic area (VLPO) and the tuberomammillary nucleus (TMN), which play important roles in sleep-wake regulation, according to the 'flip-fop' model to explore this mechanism (Lazarus et al., 2013; Saper et al., 2001) .
MATERI ALS AND METHODS

Animals
Male specific pathogen-free inbred C57BL/6J mice, weighing 20-26 g (11-13 weeks old), were obtained from the Laboratory Animal Center of the Chinese Academy of Sciences (Shanghai, China). Animals were housed at an ambient temperature of 22 AE 0.5°C at a relative humidity of 60 AE 2% and an automatically controlled 12 h light/12 h dark cycle (lights on at 07:00 hours, illumination intensity %100 lux). These animals had ad libitum access to food and water. All experimental protocols were approved by the Animal Administrative Committee of Shanghai. Every effort was made to minimize the number of animals used and their experienced pain and discomfort.
Reagents
Helicid (Kunming Baker Norton Pharmaceutical, Kunming China) and gabapentin (Chongqing Sai Wei Pharmaceutical, Chongqing, China) were both dissolved in sterile saline containing 0.5% sodium salt of carboxymethylcellulose before use.
Neuropathic pain model
Animals were anaesthetized with 5% chloral hydrate (360 mg kg À1 , i.p.). A partial nerve injury model was produced by tying a tight ligature with silk suture around, approximately from one-third to half the diameter of the sciatic nerve on the ipsilateral side. The nerve of shamoperated mice was exposed but not ligated Wang et al., 2015a) . Both PSL-and sham-operated mice were housed in separate cages to recover for at least 7 days before tests. Mechanical allodynia was measured (see below) in all animals before and after surgery.
Measurement of mechanical allodynia
Mechanical allodynia was quantified by measuring hind paw withdrawal response . Briefly, animals were placed in a clear test chamber with a framed metal mesh floor and allowed to habituate for 60 min prior to the test. Von Frey monofilaments (bending force range from 0.1 to 8 g; North Coast Medical, San Jose, CA, USA) were applied perpendicularly to the mid-plantar surface of the hind paw. Clear paw withdrawal, shaking and licking were all considered nociceptive-like responses (Dixon, 1980) . A 2-g filament was used at first. The force decreased when animals responded and increased when they did not. Five more stimuli were performed and the response threshold was calculated using the up-down Excel program provided by Basbaum's laboratory (UCSF, San Francisco, CA, USA).
Polygraphic recordings and vigilance state analysis
Under 5% chloral hydrate (360 mg kg À1 , i.p.) anaesthesia, mice that firstly underwent PSL surgery mentioned above were implanted with electrodes that consisted of two stainless steel screws (1 mm in diameter) and two Teflon-coated, insulated stainless steel wires for polysomnographic electroencephalograms (EEG) and electromyogram (EMG) recordings at the same time according to our previous studies (Huang et al., 2006; Liu et al., 2014) . After recovery for 10 days, mice were transferred to the recording chamber, and were given a 4-day period of habituation. Then, polygraphic recordings were recorded for 48 h in freely moving mice.
Cortical EEG and EMG signals were amplified, filtered (EEG, EMG, and then digitized at a sampling rate of 128 Hz, and recorded using SleepSign (Kissei Comtec, Nagano, Japan) as earlier described (Huang et al., 2006; Qu et al., 2010; Wang et al., 2015b) . When completed, data were automatically scored, if necessary, visually examined, off-line at 4-s epochs as wakefulness, rapid eye movement (REM) and non-rapid eye movement (NREM) sleep by SleepSign according to standard criteria. 
Pharmacological treatments
To study the anti-nociceptive effect of helicid in PSL mice, mechanical allodynia was tested before and at 1, 3, 6 and 9 h after helicid or gabapentin (100 mg kg À1 , reference drug) was administered intragastrically (i.g.). To evaluate the dosedependent relationship of the anti-allodynic effect, increasing doses of helicid (25, 50, 100, 200 or 400 mg kg À1 ) were used; 100, 200 or 400 mg kg À1 helicid and 100 mg kg À1 gabapentin or vehicle was administered i.g. before lights were turned on, to study the effect of helicid on sleep disturbances under neuropathic pain-like conditions. Furthermore, 400 mg kg À1 helicid was administered i.g. at 21:00 hours to estimate possible drowsiness effects on normal mice.
c-Fos immunohistochemistry
Four groups of mice were studied: PSL + vehicle; PSL + 400 mg kg À1 helicid; sham + vehicle; and sham + 400 mg kg À1 helicid. Each group was given either vehicle or helicid i.g. at 07:00 hours. After 120 min, mechanical allodynia was measured in all animals. All animals were then killed for immunohistochemical experiments as previously described (Chen et al., 2011) . The mice were anaesthetized with 5% chloral hydrate and perfused with saline solution followed by ice-cold 4% paraformaldehyde. Brains were removed, postfixed, and then dipped in sucrose with a gradient concentration from 10 to 30% for cryoprotection. Thereafter, frozen sections of brain were cut into 30-lm-thick coronal planes with a freezing microtome (Microm HM 525, Thermoscientific, Germany). Sections were stored in a cryoprotectant solution at À20°C for histological analysis. Free-floating sections were incubated with 0.3% hydrogen peroxide in 0.1 M phosphate-buffered saline (PBS; pH 7.4) for 15 min at room temperature to quench endogenous peroxidase activity. After rinsing in PBS, sections were sequentially incubated at room temperature in 3% normal goat serum and 0.25% Triton X-100 in PBS (PBS-T) for 1 h, and primary rabbit anti-c-Fos (1 : 5000; Millipore, Boston, MA, USA) antibody diluted in PBS-T with 0.02% sodium azide overnight. The sections were then rinsed with PBS and incubated for 2 h in biotinylated goat anti-rabbit secondary antiserum (1 : 1000; Jackson ImmunoResearch, West Grove, PA, USA). All sections were then treated with avidin-biotinperoxidase complex (1 : 1000; Vectastain ABC Elite Kit, Vector Laboratories, Burlingame, CA, USA) for 1 h. The peroxidase reaction was visualized with 0.05% 3,3 0 -diaminobenzidine (Sigma-Aldrich, Saint Louis, MO, USA) in 0.1 M PBS and 0.01% hydrogen peroxide. After terminating the reaction with PBS-azide, sections were mounted, dehydrated and covered. Adjacent sections were incubated as controls, without the primary antibody to confirm a lack of non-specific staining. Sections were examined under bright-field illumination using an Olympus BX51 microscope (Japan). Images were captured with a digital camera (DP72, Olympus, Japan).
Statistical analysis
All results were expressed as means AE SEM. For mechanical threshold before and after surgery, a paired Student's ttest was assessed. For mechanical threshold and vigilance stages among PSL mice treated with vehicle, helicid and gabapentin, one-way ANOVA was used, followed by Fisher's probable least-squares difference (PLSD) test. Time-course changes in mechanical thresholds and sleep-wake profiles of PSL mice treated with different agents were compared using repeated-measures ANOVA followed by PLSD. Two-way ANOVA followed by PLSD was used to assess the number of c-Fosimmunoreactive neurons. In all cases, P-values < 0.05 were considered statistically significant.
RESULTS
Helicid increased mechanical allodynia caused by PSL
Neuropathy induced by PSL caused remarkable mechanical allodynia in mice. Compared with mice in the sham group, mechanical thresholds (P < 0.01; Fig. 2a ) were significantly attenuated in PSL mice on the seventh day after surgery, while no change was found in the sham group. This result was consistent with previous studies in which tactile allodynia lasted for at least 35 days after PSL .
To investigate the effects of helicid on tactile allodynia, mechanical thresholds were assessed before and 1, 3, 6 and 9 h after administration in PSL mice. The time-course curves in Fig. 2b showed that intragastric administration of helicid at 400 mg kg À1 remarkably increased the mechanical threshold for 6 h (P < 0.01; Fig. 2b ), which was similar to the positive control gabapentin at a dose of 100 mg kg À1 , whose effect could last for 9 h (P < 0.01; Fig. 2b ). The decline of mechanical threshold of PSL mice treated with vehicle was considered as a result of pain sensitization over repeated tests.
To explore the dose-dependency of anti-nociceptive effects, gradient doses of helicid from 25 mg kg À1 to 400 mg kg
À1
were given to PSL mice. When helicid at a dose of 25 or 50 mg kg À1 was given, there was no change in mechanical threshold. Helicid given at 100, 200 and 400 mg kg À1 , and gabapentin at 100 mg kg
, significantly increased the mechanical threshold by 2.5-(P < 0.05), 2.8-(P < 0.01), 3.1-(P < 0.01) and 2.6-fold (P < 0.01), respectively (Fig. 2c ), in comparison with vehicle administration in PSL mice. The antinociceptive effects of helicid were not different from those of gabapentin at 100 mg•kg À1 . These results indicated that helicid exerts analgesic effects on mechanical allodynia induced by PSL in a dose-dependent manner. (Fig. 3b) revealed that pretreatment of helicid at 400 mg kg À1 caused a significant increase in NREM sleep (F 1,74 = 10.145, P < 0.01) and a decrease in wakefulness (F 1,74 = 9.989, P < 0.01) in PSL mice, compared with vehicle-treated mice. Helicid increased the hourly NREM sleep time of PSL mice by 1.48-(P < 0.05) and 1.52-fold (P < 0.05), respectively, at the second and third hour after i.g. administration. Correspondingly, 0.53-(P < 0.05) and 0.52-fold (P < 0.05) decreases in wakefulness were found. REM sleep remained the same, except for the third hour after treatment (a 2.24-fold increase, P < 0.01). There was no subsequent disturbance of sleep architecture observed during the subsequent period. Figure 3c summarizes the total amounts of time spent in NREM sleep, REM sleep and wakefulness in the first 3 h after treatment. Compared with the vehicle, pretreatment with helicid in PSL mice at 200 and 400 mg kg À1 , or positive control gabapentin at 100 mg kg
, significantly increased NREM sleep by 1.27-(P < 0.05), 1.35-(P < 0.05) and 1.31-fold (P < 0.05), and decreased wakefulness by 0.28-(P < 0.05), 0.37-(P < 0.01) and 0.31-fold (P < 0.01), respectively. The duration of REM sleep did not change in the PSL group. These results indicated that helicid increased NREM sleep in PSL mice.
We also investigated the EEG power spectra of NREM sleep and REM sleep of PSL mice. The power of each 0.5-Hz bin was first averaged across the sleep stages individually, and then normalized by calculating the percentage of each bin from the total power (0-24.75 Hz) of the individual animal. As shown in Fig. 3d , there was no significant difference in the EEG power density of NREM sleep or REM sleep between the helicid and vehicle groups, which meant the sleep induced by helicid tended to be physiological.
No drowsiness effect of helicid in normal mice
To determine the hypnotic effect of helicid on sleep-wake profiles in the active phase, helicid at a dose of 400 mg kg À1 or vehicle was administered i.g. into normal mice at 21:00 hours when mice spent the most time in wakefulness. No difference in sleep-wake profiles was found (Fig. 4) . We concluded that helicid did not elicit drowsiness in the active phase in normal mice.
Effect of helicid on c-Fos expression in the rACC, VLPO and TMN of PSL and sham mice
To further explore the mechanisms by which helicid alleviates pain and improves sleep quality, an immunohistochemical study of c-Fos-positive neurons was performed in the rACC, which is reported to modulate negative affective components of nociceptor stimulation (Johansen et al., 2001) , as well as in the sleep centre in the anterior hypothalamus VLPO, and the arousal centre in the TMN (Lazarus et al., 2013) . These brain regions were verified according to the mouse atlas (Paxinos and Franklin, 2013) , as shown in Fig. 5 .
As shown in Fig. 5m , compared with the control group, the mechanical threshold in PSL mice significantly increased after the helicid administration of 400 mg kg À1 (P < 0.01), but the effect was not observed in the sham mice, which suggested that helicid exerted analgesic effects in the PSL group in this experiment. ) treatment on mechanical threshold of PSL mice. Gabapentin was used as the positive control drug. Values are expressed as means AE SEM (n = 7-10). *P < 0.05, **P < 0.01 indicate significant differences compared with vehicle value in PSL group; # P < 0.05, ## P < 0.01 indicate significant differences compared with helicid at a dose of 25 mg kg The horizontal open and filled bars on the x-axes, respectively, indicate the 12 h light and 12 h dark periods. Values are expressed as means AE SEM (n = 7-9). *P < 0.05, **P < 0.01 indicates significant differences from vehicle group as assessed by repeated-measures ANOVA followed by the probable least-squares difference (PLSD) test. (c) Dose-response effect on total time spent in NREM sleep, REM sleep and wakefulness for 3 h after i.g. administration of vehicle and helicid in PSL mice. Open and filled bars represent the profiles of vehicle and helicid or gabapentin treatments, respectively. Values are expressed as means AE SEM (n = 7-9). *P < 0.05, **P < 0.01 indicate significant differences from vehicle value in PSL group, assessed by one-way ANOVA followed by the PLSD test. ) in PSL mice decreased it in TMN by 82% (P < 0.01; Fig. 5o ) and increased it in VLPO by 2.6-fold (P < 0.05; Fig. 5p ). This effect was not found in the sham mice.
DI SCUSSION
In recent years, helicid has drawn greater attention because of its sedative, analgesic, hypnotic effects, and low toxicity Yi et al., 2008) . The neuroprotective role of helicid is comprehensive, involving excitotoxicity, nitric monoxide systems, neuroglia, biomembranes, oxidative neurotoxicity and apoptosis (Yue et al., 2014) . In our study, we evaluated the effects of helicid on neuropathic pain and co-morbid insomnia using the PSL model mice. Intragastric administration of helicid could effectively recover the mechanical threshold reduced by PSL, increase NREM sleep and decrease wakefulness in a dose-dependent manner in PSL mice during the light phase. The antinociceptive and hypnotic effects lasted about 6 h and 3 h, respectively. There was no hypnotic effect observed in normal mice. These data suggest that helicid might only improve sleep disorders in patients with pain, but did not cause drowsiness in healthy people.
The rACC is thought to be one of the areas that encodes negative affective components of nociceptor stimulation (Johansen et al., 2001; Qu et al., 2011) . TMN and VLPO play important roles in sleep-wake regulation according to the 'flip-flop' model (Lazarus et al., 2013; Saper et al., 2001) . In our study, we found that PSL led to an increase of c-Fos expression in the rACC and TMN, as well as a reduction in VLPO, which was not observed in sham mice, and administration of helicid recovered these changes. It should be noted that, in view of the possible causality between pain relief and improvement of sleep disturbances that were elicited by administration of helicid, the change of c-Fos expression in ACC might be a direct response of pain relief, while the changes in TMN and VLPO would be a secondary effect of the pain relief and its follow-up sleep improvements. The data further confirmed the anti-nociceptive and hypnotic effects of helicid, which might be helpful for further exploring its mechanisms.
However, despite its low toxicity, the effective dose of helicid as a therapeutic agent is relatively high due to its low bioavailability, which may result from poor cell membrane penetration, especially when the hypnotic effect is expected (such as with 200-400 mg kg À1 for mice in our study). Some studies are exploring new analogues to enhance helicid activity by changing conformation of specific groups or introducing lipophilic groups into its structure. Ester derivatives of helicid exert higher activities than the prototype, probably owing to the improvement of membrane penetration Yi et al., 2008) . Besides, Yang et al. also reported a novel and highly efficient regioselective route to helicid esters (Yang et al., 2013) . This research suggested more possibilities to explore efficient agents ameliorated from helicid.
In conclusion, our results proved that the PSL model induced mechanical allodynia, sleep disturbances and c-Fos changes in the rACC, TMN and VLPO of mice. Intragastric administration of helicid could exert anti-nociceptive effects for 6 h and increased NREM sleep for 3 h after administration, rebound changes of c-Fos expression in the rACC and TMN and VLPO.
Therefore, we concluded that helicid could be an effective treatment for neuropathic pain and co-morbid insomnia. Values are expressed as means AE SEM (n = 6-8), *P < 0.05, **P < 0.01 indicate significant differences from vehicle value in the PSL group; # P < 0.05, ## P < 0.01 indicates significant differences compared with sham group, assessed by two-way ANOVA followed by probable least-squares difference (PLSD) test. 3V, the third ventricle; OX, optic chiasm; rACC, rostal anterior cingulate cortex; TMN, tuberomammillary nucleus; Tu, olfactory tubercle; VLPO, ventrolateral preoptic area.
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